KEROS ALERT: Bragar Eagel & Squire, P.C. is Investigating Keros Therapeutics, Inc. on Behalf of Keros Stockholders and Encourages Investors to Contact the FirmNEW YORK, Jan. 24, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Keros Therapeutics, Inc. (“Keros” or the “Company”) (
NASDAQKROS) on behalf of Keros stockholders. Our investigation concerns whether Keros has violated the federal securities laws and/or engaged in other unlawful business practices.
Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Keros Therapeutics, Inc. (KROS)
The law firm of Kirby McInerney LLP is investigating potential claims against Keros Therapeutics, Inc. (“Keros” or the “Company”) (
NASDAQKROS). The investigation concerns whether Keros and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices.
Keros Therapeutics, Inc. Investigation Ongoing: Contact Levi & Korsinsky to Discuss Your Rights - KROSNEW YORK, NY / ACCESSWIRE / December 17, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Keros Therapeutics, Inc. ("Keros Therapeutics, Inc.") (
NASDAQKROS) concerning possible violations of federal securities laws.
Shareholders that lost money on Keros Therapeutics, Inc.(KROS) should contact Levi & Korsinsky about Securities Fraud Investigation - KROSNEW YORK, NY / ACCESSWIRE / December 16, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Keros Therapeutics, Inc. ("Keros Therapeutics, Inc.") (
NASDAQKROS) concerning possible violations of federal securities laws.
Keros Therapeutics Inc. (NASDAQ: KROS) Near the Top of Equities by Percentage Gain on 1/4Keros Therapeutics, Inc. (
NASDAQKROS) is one of today’s top gainers. The company’s shares have moved 1.08% on the day to $27.96.
Levi & Korsinsky Announces an Investigation on Behalf of Keros Therapeutics, Inc. (KROS) Shareholders Who May Have Been Affected by FraudNEW YORK, NY / ACCESSWIRE / December 16, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Keros Therapeutics, Inc. ("Keros Therapeutics, Inc.") (
NASDAQKROS) concerning possible violations of federal securities laws.
BioMedNewsBreaks – Keros Therapeutics Inc. (NASDAQ: KROS) Presents Clinical and Preclinical Data from Its Lead Hematological Programs at 64th ASH EventKeros (
NASDAQKROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological, pulmonary and cardiovascular disorders, announced that it presented clinical and preclinical data at the 64th American Society of Hematology (“ASH”) Annual Meeting and Exposition. The event was held in person and virtually from Dec. 10 -13, 2022. “We are pleased to present clinical and preclinical data from our lead hematological programs at ASH this year. In our ongoing phase 2 clinical trial in MDS, we observed a sustained response with longer-term treatment with KER-050 across all transfusion burdens. Data from our ongoing phase 2 trial in MF support the potential for KER-050 to treat multiple cytopenias as either a monotherapy or in combination with ruxolitinib,” said Jasbir S. Seehra, Ph.D., president and CEO of Keros. “In addition, clinical data from one IRIDA patient in our phase 2 clinical trial of KER-047 was suggestive of iron redistribution consistent with KER-047’s mechanism of action.”
